Actively Recruiting

Phase 2
Age: 16Years - 70Years
All Genders
NCT03194815

IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2

Led by University of Cambridge · Updated on 2025-03-30

70

Participants Needed

10

Research Sites

491 weeks

Total Duration

On this page

Sponsors

U

University of Cambridge

Lead Sponsor

U

University of Oxford

Collaborating Sponsor

AI-Summary

What this Trial Is About

A randomised phase II double-blinded placebo-controlled trial designed to explore the utility of immunotherapy for patients with acute psychosis associated with anti-neuronal membranes (NMDA-receptor or Voltage Gated Potassium Channel). Primary objective: To test the efficacy of immunotherapy (IVIG and rituximab) for patients with acute psychosis associated with anti-neuronal membranes. Secondary objective: To test safety of immunotherapy (IVIG and rituximab) for patients with acute psychosis associated with anti-neuronal membranes.

CONDITIONS

Official Title

IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2

Who Can Participate

Age: 16Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Acute psychosis longer than 2 weeks, either first episode or relapse after remission (remission means mild or no symptoms for at least 6 months)
  • Presence of serum or cerebrospinal fluid neuronal membrane autoantibodies at pathological levels (including NMDAR, LGI1, and others)
  • Psychosis symptoms scoring 4 or more on at least one of these PANSS items: P1, P2, P3, N1, N4, N6, G5, or G9
Not Eligible

You will not qualify if you...

  • Current psychosis episode lasting more than 24 months
  • Having a severe neurological disease at the same time
  • Signs of current acute encephalopathy
  • Hepatitis or HIV infection, or pregnancy
  • Contraindications to any trial medication
  • Currently enrolled in another clinical trial involving investigational medicinal products

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 10 locations

1

Cambridge University Hospitals NH Foundation Trust

Cambridge, United Kingdom

Actively Recruiting

2

Royal Devon and Exeter NHS Foundation Trust

Exeter, United Kingdom

Actively Recruiting

3

NHS Greater Glasgow and Clyde

Glasgow, United Kingdom

Actively Recruiting

4

The Walton Centre NHS Foundation Trust

Liverpool, United Kingdom

Actively Recruiting

5

University College London Hospitals Nhs Foundation Trust

London, United Kingdom, NW1 2PG

Actively Recruiting

6

King's College Hospital NHS Foundation Trust

London, United Kingdom

Actively Recruiting

7

Salford Royal NHS Foundation Trust

Manchester, United Kingdom

Actively Recruiting

8

Nottingham University Hospitals NHS Trust

Nottingham, United Kingdom

Actively Recruiting

9

Oxford University Hospitals NHS Foundation Trust

Oxford, United Kingdom

Actively Recruiting

10

Sheffield Teaching Hospitals NHS Foundation Trust

Sheffield, United Kingdom

Actively Recruiting

Loading map...

Research Team

A

Alastdair Coles, PhD FRCP

CONTACT

B

Belinda Lennox, DM MRCPsych

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here